Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1977 Apr 23;116(8):851–855.

Metabolic balance studies in patients with Paget's disease receiving salmon calcitonin over long periods.

D G Oreopoulos, H Husdan, J Harrison, H E Meema, K G McNeill, T M Murray, R Ogilvie, A Rapoport
PMCID: PMC1879370  PMID: 856428

Abstract

Metabolic balance and calcium kinetic studies were performed in four patients with Paget's disease before treatment with salmon calcitonin and during the early and late stages of the treatment, which lasted 9 to 19 months, A significant decrease in bone turnover and 24-hour urine hydroxyproline and serum alkaline phosphatase values was observed in all patients. In contrast, the calcium, phosphorus and magnesium balances did not change significantly. In agreement with this, the partial body calcium, measured by in vivo neutron activation analysis, did not change. Intestinal calcium absorption increased initially, but returned to baseline levels 9 to 19 months after the study began. During the initial period there was a small, significant, but transient decrease in tubular reabsorption of phosphorus; this was accompanied by a significant decrease in serum phosphorus values--probably a direct effect of calcitonin rather than evidence of secondary hyperparathyroidism. Administration of salmon calcitonin to patients with Paget's disease decreases bone turnover without affecting calcium and phosphorus balances.

Full text

PDF
851

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avramides A., Baker R. K., Wallach S. Metabolic effects of synthetic salmon calcitonin in Paget's disease of bone. Metabolism. 1974 Nov;23(11):1037–1046. doi: 10.1016/0026-0495(74)90070-5. [DOI] [PubMed] [Google Scholar]
  2. Bell N. H., Avery S., Johnston C. C., Jr Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia. J Clin Endocrinol Metab. 1970 Sep;31(3):283–290. doi: 10.1210/jcem-31-3-283. [DOI] [PubMed] [Google Scholar]
  3. Cochran M., Peacock M., Sachs G., Nordin B. E. Renal effects of calcitonin. Br Med J. 1970 Jan 17;1(5689):135–137. doi: 10.1136/bmj.1.5689.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Harrison J. E., Hitchman A. J., Finlay J. M., McNeill K. G. Calcium kinetic studies in patients with malabsorption syndrome. Gastroenterology. 1969 Apr;56(4):751–757. [PubMed] [Google Scholar]
  5. Harrison J. E., McNeill K. G., Wilson D. R., Oreopoulos D. G., Krondl A., Finlay J. M. An evaluation of isotopic calcium absorption tests. Clin Biochem. 1973 Dec;6(4):237–245. doi: 10.1016/s0009-9120(73)80032-3. [DOI] [PubMed] [Google Scholar]
  6. Harrison J. E., Williams W. C., Watts J., McNeill K. A bone calcium index based on partial-body calcium measurements by in vivo activation analysis. J Nucl Med. 1975 Feb;16(2):116–122. [PubMed] [Google Scholar]
  7. Husdan H., Rapoport A. Estimation of calcium, magnesium, and phosphorus in diet and stool. Clin Chem. 1969 Aug;15(8):669–679. [PubMed] [Google Scholar]
  8. Kivirikko K. I., Laitinen O., Prockop D. J. Modifications of a specific assay for hydroxyproline in urine. Anal Biochem. 1967 May;19(2):249–255. doi: 10.1016/0003-2697(67)90160-1. [DOI] [PubMed] [Google Scholar]
  9. MEEMA H. E., HARRIS C. K., PORRETT R. E. A METHOD FOR DETERMINATION OF BONE-SALT CONTENT OF CORTICAL BONE. Radiology. 1964 Jun;82:986–997. doi: 10.1148/82.6.986. [DOI] [PubMed] [Google Scholar]
  10. McNeill K. G., Thomas B. J., Sturtridge W. C., Harrison J. E. In vivo neutron activation analysis for calcium in man. J Nucl Med. 1973 Jul;14(7):502–506. [PubMed] [Google Scholar]
  11. Murray T. M., Keutmann H. T. The immunochemical specificity of antisera to bovine parathyroid hormone: an approach to region-specific radioimmunoassay. J Endocrinol. 1973 Mar;56(3):493–501. doi: 10.1677/joe.0.0560493. [DOI] [PubMed] [Google Scholar]
  12. Murray T. M., Peacock M., Powell D., Monchik J. M., Potts J. T., Jr Non-autonomy of hormone secretion in primary hyperparathyroidism. Clin Endocrinol (Oxf) 1972 Jul;1(3):235–246. doi: 10.1111/j.1365-2265.1972.tb00394.x. [DOI] [PubMed] [Google Scholar]
  13. Shai F., Baker R. K., Wallach S. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone. J Clin Invest. 1971 Sep;50(9):1927–1940. doi: 10.1172/JCI106685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Veer J. V., Bijvoet O. L., Smeenk D. Effects of long-term porcine calcitonin administration in patients with Paget's disease or osteoporosis. Calcif Tissue Res. 1970;(Suppl):88–88. doi: 10.1007/BF02152367. [DOI] [PubMed] [Google Scholar]
  15. Wallach S., Avramides A., Flores A., Bellavia J., Cohn S. Skeletal turnover and total body elemental composition during extended calcitonin treatment of Paget's disease. Metabolism. 1975 Jun;24(6):745–753. doi: 10.1016/0026-0495(75)90042-6. [DOI] [PubMed] [Google Scholar]
  16. Woodhouse N. J., Bordier P., Fisher M., Joplin G. F., Reiner M., Kalu D. N., Foster G. V., MacIntyre I. Human calcitonin in the treatment of Paget's bone disease. Lancet. 1971 Jun 5;1(7710):1139–1143. doi: 10.1016/s0140-6736(71)91657-6. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES